Inflammation and Post-Stroke Depression

Active, not recruiting

Phase N/A Results N/A

Trial Description

This study is being done to see if there is a relationship between stroke, post-stroke depression, and measures of inflammatory and/or stress compounds in the blood. Brain injury, as caused by stroke, leads to an inflammatory response in the brain which in turn can influence inflammatory and stress responses in other parts of the body outside of the brain. These responses can be measured by analyzing various substances in the blood and in the white blood cells. The investigators will measure these substances (cytokines, glucocorticoids) and compare them to the absence, presence, or degree of depression that the investigators will determine by neurological and psychological testing. The investigators will be drawing blood for this study on admission, at or around day 3, at or around day 7 and at or around day 90, which is not part of routine stroke care. The investigators will be asking subjects to participate in answering question/scales on these same days, some of these questionnaires are also not part of routine stroke care. Standard stroke care is being done other than blood drawing/participating in answering questions/scales. Approximately 25 people will be enrolled over one year.

Detailed Description

Depression is a common long-term outcome of acute ischemic stroke (AIS), and can impede recovery, increase stroke recurrence, and influence mortality from stroke. Based on literature reviewed below, the investigators propose the novel over-arching hypothesis: that post-stroke depression (PSD) occurs in patients who show elevated production of proinflammatory immune cytokines during and/or after stroke, and at the same time present with reduced sensitivity to the immunosuppressive effects of glucocorticoids, which otherwise would be expected to have down-regulated cytokine production.

Conditions

Trial Design

  • Perspective: Prospective
  • Sampling: Non-Probability Sample

Trial Population

Subjects with acute iechemic stroke

Outcomes

Type Measure Time Frame Safety Issue
Primary • The analysis of the presence of specific inflammatory markers 90 days No
Primary presence of depression in people with ischemic stroke 90 days No
Secondary Measurement and identification stroke location 90 days No

Biospecimen Retention:Samples Without DNA - whole blood serum

Sponsors